Boosting therapeutic potency of antibodies by taming Fc domain functions
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Boosting therapeutic potency of antibodies by taming Fc domain functions
Authors
Keywords
-
Journal
EXPERIMENTAL AND MOLECULAR MEDICINE
Volume 51, Issue 11, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-18
DOI
10.1038/s12276-019-0345-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer
- (2018) Maren Knödler et al. BRITISH JOURNAL OF CANCER
- Safety, Tolerability, and Pharmacokinetics of MEDI8897, an Extended Half-Life Single-Dose Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants
- (2018) Joseph B. Domachowske et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- The Increasingly Human and Profitable Monoclonal Antibody Market
- (2018) António L. Grilo et al. TRENDS IN BIOTECHNOLOGY
- Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
- (2018) Martin R. Gaudinski et al. PLOS MEDICINE
- A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus
- (2018) Bronwyn M. Gunn et al. Cell Host & Microbe
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
- (2018) Johnny Mahlangu et al. NEW ENGLAND JOURNAL OF MEDICINE
- OUP accepted manuscript
- (2018) PROTEIN ENGINEERING DESIGN & SELECTION
- Targeting FcRn to Generate Antibody-Based Therapeutics
- (2018) E. Sally Ward et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study
- (2018) Johannes Oldenburg et al. HAEMOPHILIA
- Fcγ Receptor Function and the Design of Vaccination Strategies
- (2017) Stylianos Bournazos et al. IMMUNITY
- An “Fc-Silenced” IgG1 Format With Extended Half-Life Designed for Improved Stability
- (2017) M. Jack Borrok et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Emicizumab Prophylaxis in Hemophilia A with Inhibitors
- (2017) Johannes Oldenburg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modulating IgG effector function by Fc glycan engineering
- (2017) Tiezheng Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- IgG Fc engineering to modulate antibody effector functions
- (2017) Xinhua Wang et al. Protein & Cell
- Engineered Soluble Monomeric IgG1 Fc with Significantly Decreased Non-Specific Binding
- (2017) Chunyu Wang et al. Frontiers in Immunology
- Corrigendum: Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins
- (2017) Ji-Hee Ha et al. Frontiers in Immunology
- Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development
- (2017) Wei Li et al. Frontiers in Immunology
- Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production
- (2017) Cristina Capuano et al. OncoImmunology
- Immunoglobulin isotype knowledge and application to Fc engineering
- (2016) Randall J Brezski et al. CURRENT OPINION IN IMMUNOLOGY
- Fc Engineering to Improve the Function of Therapeutic Antibodies
- (2016) Futa Mimoto et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Immunoregulatory functions of immune complexes in vaccine and therapy
- (2016) Yu‐mei Wen et al. EMBO Molecular Medicine
- Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability
- (2016) Frederick W. Jacobsen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody
- (2016) Di Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
- (2016) Tilman Schlothauer et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors
- (2016) Jürgen Borlak et al. Oncotarget
- Advances in Therapeutic Fc Engineering – Modulation of IgG-Associated Effector Functions and Serum Half-life
- (2016) Abhishek Saxena et al. Frontiers in Immunology
- Engineering antibodies for dual specificity and enhanced potency
- (2015) Sanghwan Ko et al. BIOTECHNOLOGY AND BIOPROCESS ENGINEERING
- Bispecific antibodies
- (2015) Roland E. Kontermann et al. DRUG DISCOVERY TODAY
- Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms
- (2015) C. M. Kurbacher et al. ONCOLOGIST
- Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?
- (2015) Mireia Pelegrin et al. TRENDS IN MICROBIOLOGY
- Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab
- (2015) Andreas Seeber et al. Oncotarget
- Selective Antibody Intervention of Toll-like Receptor 4 Activation through Fc γ Receptor Tethering
- (2014) Limin Shang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Macrophages eliminate circulating tumor cells after monoclonal antibody therapy
- (2014) Nuray Gül et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting the Neonatal Fc Receptor for Antigen Delivery Using Engineered Fc Fragments
- (2014) W. Mi et al. JOURNAL OF IMMUNOLOGY
- Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases
- (2014) Tianlei Ying et al. mAbs
- Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab
- (2013) J. Golay et al. BLOOD
- An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations
- (2013) Omid Vafa et al. METHODS
- Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131
- (2013) F. Mimoto et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Revisiting the Role of Glycosylation in the Structure of Human IgG Fc
- (2012) M. Jack Borrok et al. ACS Chemical Biology
- Effective Phagocytosis of Low Her2 Tumor Cell Lines with Engineered, Aglycosylated IgG Displaying High FcγRIIa Affinity and Selectivity
- (2012) Sang Taek Jung et al. ACS Chemical Biology
- Soluble Monomeric IgG1 Fc
- (2012) Tianlei Ying et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- With or Without Sugar? (A)glycosylation of Therapeutic Antibodies
- (2012) Dmitrij Hristodorov et al. MOLECULAR BIOTECHNOLOGY
- A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
- (2012) Takehisa Kitazawa et al. NATURE MEDICINE
- Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond
- (2012) P. Mark Hogarth et al. NATURE REVIEWS DRUG DISCOVERY
- Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice
- (2011) Mayuka Horikawa et al. JOURNAL OF CLINICAL INVESTIGATION
- Antibody-Mediated Coengagement of FcγRIIb and B Cell Receptor Complex Suppresses Humoral Immunity in Systemic Lupus Erythematosus
- (2011) Holly M. Horton et al. JOURNAL OF IMMUNOLOGY
- Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells
- (2011) K. Baker et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- IgG2m4, an engineered antibody isotype with reduced Fc function
- (2010) Zhiqiang An et al. mAbs
- Enhanced antibody half-life improves in vivo activity
- (2010) Jonathan Zalevsky et al. NATURE BIOTECHNOLOGY
- Optimization of Fc-mediated effector functions of monoclonal antibodies
- (2009) William R Strohl CURRENT OPINION IN BIOTECHNOLOGY
- Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
- (2009) Frédéric Bibeau et al. JOURNAL OF CLINICAL ONCOLOGY
- Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates
- (2009) Y. A. Yeung et al. JOURNAL OF IMMUNOLOGY
- Structural characterization of a human Fc fragment engineered for extended serum half-life
- (2009) Vaheh Oganesyan et al. MOLECULAR IMMUNOLOGY
- Receptor-mediated phagocytosis elicits cross-presentation in nonprofessional antigen-presenting cells
- (2009) A. Giodini et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Aglycosylated IgG variants expressed in bacteria that selectively bind Fc RI potentiate tumor cell killing by monocyte-dendritic cells
- (2009) S. T. Jung et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural characterization of a human Fc fragment engineered for lack of effector functions
- (2008) Vaheh Oganesyan et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Influence of variants of Fc receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor therapy in rheumatoid arthritis
- (2008) J D Canete et al. ANNALS OF THE RHEUMATIC DISEASES
- Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc RI, Fc RIII, and Fc RIV
- (2008) V. Minard-Colin et al. BLOOD
- Specificity and affinity of human Fc receptors and their polymorphic variants for human IgG subclasses
- (2008) P. Bruhns et al. BLOOD
- Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40
- (2008) E Oflazoglu et al. BRITISH JOURNAL OF CANCER
- Intravenous immunoglobulins induce CD32-mediated platelet aggregationin vitro
- (2008) A. Pollreisz et al. BRITISH JOURNAL OF DERMATOLOGY
- Molecular engineering and design of therapeutic antibodies
- (2008) Leonard G Presta CURRENT OPINION IN IMMUNOLOGY
- β2-Microglobulin Deficient Mice Catabolize IgG More Rapidly Than FcRn-α-Chain Deficient Mice
- (2008) Jonghan Kim et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Optimization of antibody binding to Fc RIIa enhances macrophage phagocytosis of tumor cells
- (2008) J. O. Richards et al. MOLECULAR CANCER THERAPEUTICS
- Structural characterization of a mutated, ADCC-enhanced human Fc fragment
- (2008) Vaheh Oganesyan et al. MOLECULAR IMMUNOLOGY
- Podocytes use FcRn to clear IgG from the glomerular basement membrane
- (2008) S. Akilesh et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dependence of antibody-mediated presentation of antigen on FcRn
- (2008) S.-W. Qiao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Macrophage activation and polarization
- (2007) Fernando Oneissi Martinez Frontiers in Bioscience-Landmark
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started